Literature DB >> 1978551

Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. Evidence for a bimodal expression of clinical and biological symptoms.

S Blanche1, M Tardieu, A Duliege, C Rouzioux, F Le Deist, K Fukunaga, M Caniglia, C Jacomet, A Messiah, C Griscelli.   

Abstract

To better define the clinical and biological evolution of infants after vertical human immunodeficiency virus type 1 infection, we analyzed 94 consecutive infected patients followed up after their first clinical symptoms. The expression of clinical symptoms and biological abnormalities followed a bimodal distribution, some patients having an early and severe disease and the others having a slowly progressive one. One third of our patients suffered from early onset of opportunistic infection (OI). These patients had a significantly higher incidence of severe encephalopathy compared with patients without OI. The rate of survival at 3 years was 48% +/- 24%. In contrast, the patients without early OI or severe encephalopathy had a probability of survival at 3 years of 97% +/- 3%. This probability was not modified by the occurrence of bacterial infection or lymphoid interstitial pneumonitis. Lymphoid interstitial pneumonitis occurred at a mean age of 29 months, significantly later than OI or severe encephalopathy. Laboratory results at initial examination were correlated with clinical symptoms. Thus, when the number of CD4 lymphocytes was less than 500/mm3, children suffered more frequently from life-threatening symptoms (OI and severe encephalopathy): 15 of 22 vs 14 of 69. The same was true when the lymphocytes did not proliferate after antigenic stimulation, when anti-p18 and/or anti-p25 antibodies were absent in the serum, and when p24 antigen was detected in serum. Finally, severe encephalopathy was associated with low anti-human immunodeficiency virus cerebrospinal fluid antibody titer, whereas 88% of patients with moderate or no encephalopathy had signs of intrathecal anti-human immunodeficiency virus antibody synthesis. In conclusion, a subgroup of patients expressed very early signs of severe immunodeficiency and encephalopathy, whereas the majority of patients had a longer survival and less severe clinical symptoms during their first years of life than previously thought.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1978551     DOI: 10.1001/archpedi.1990.02150350042021

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  42 in total

Review 1.  Neurotoxicity of macrophages infected by HIV1.

Authors:  M Tardieu; C Hery; S Peudenier
Journal:  Cell Biol Toxicol       Date:  1992 Jul-Sep       Impact factor: 6.691

2.  Pediatric infections.

Authors:  N E Macdonald
Journal:  Can J Infect Dis       Date:  1992-03

Review 3.  HIV infection in children.

Authors:  D Gibb; M L Newell
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

4.  In-utero infection with HIV-1 associated with suppressed lymphoproliferative responses at birth.

Authors:  B Lohman-Payne; T Sandifer; M OhAinle; C Crudder; J Lynch; M M Omenda; J Maroa; K Fowke; G C John-Stewart; C Farquhar
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

Review 5.  Infants born to HIV-1 infected women: lessons from the past decade.

Authors:  A Kaul; S Chandwani
Journal:  Indian J Pediatr       Date:  1995 Jan-Feb       Impact factor: 1.967

6.  Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival.

Authors:  Maxensia Owor; Anthony Mwatha; Deborah Donnell; Philippa Musoke; Francis Mmiro; Melissa Allen; J Brooks Jackson; Mary Glenn Fowler; Laura A Guay
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-15       Impact factor: 3.731

7.  Contact with thymic epithelial cells as a prerequisite for cytokine-enhanced human immunodeficiency virus type 1 replication in thymocytes.

Authors:  M Rothe; L Chêne; M T Nugeyre; J Braun; F Barré-Sinoussi; N Israël
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Combined therapy in human immunodeficiency virus-infected children--a 4-year experience.

Authors:  T Güngör; M Funk; R Linde; I Kynast; A Allendorf; C Lotz; S Ehrenforth; D Hofmann; B Kornhuber; W Kreuz
Journal:  Eur J Pediatr       Date:  1993-08       Impact factor: 3.183

9.  Longitudinal studies of viral sequence, viral phenotype, and immunologic parameters of human immunodeficiency virus type 1 infection in perinatally infected twins with discordant disease courses.

Authors:  C Hutto; Y Zhou; J He; R Geffin; M Hill; W Scott; C Wood
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Determining an optimal testing strategy for infants at risk for mother-to-child transmission of HIV-1 during the late postnatal period.

Authors:  Elizabeth Brown; Benjamin H Chi; Jennifer S Read; Taha E Taha; Usha Sharma; Irving F Hoffman; Cheryl Pikora; Robert Goldenberg; Susan A Fiscus
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.